SMDPY OTC
Sumitomo Pharma Co., Ltd.
1W: -1.1%
1M: +11.1%
3M: +11.7%
YTD: -9.8%
1Y: -6.1%
$10.32
-0.12 (-1.20%)
Weekly Expected Move ±7.5%
$9
$10
$10
$11
$12
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$808.1B
+8.8% ▲
5Y CAGR: -9.2%
Total Liabilities
$514.3B
-10.3% ▼
5Y CAGR: -4.9%
Shareholders Equity
$293.7B
+73.3% ▲
5Y CAGR: -12.7%
Cash & Investments
$44.5B
+11.4% ▲
5Y CAGR: -27.6%
Total Debt
$218.1B
-28.6% ▼
5Y CAGR: -4.4%
Net Debt
$173.6B
-38.5% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $203.0B | $143.5B | $29.0B | $23.1B | $44.5B |
| Short-Term Investments | $35.6B | $20.2B | $7.1B | $16.8B | $0 |
| Cash & ST Investments | $238.6B | $163.7B | $36.1B | $40.0B | $44.5B |
| Net Receivables | $151.4B | $95.9B | $81.0B | $74.8B | $135.3B |
| Inventory | $99.0B | $94.4B | $115.3B | $94.2B | $85.8B |
| Other Current Assets | $10.5B | $27.9B | $37.1B | $44.1B | $14.9B |
| Total Current Assets | $499.5B | $381.9B | $269.6B | $253.2B | $280.5B |
| Property, Plant & Equip. | $64.1B | $58.9B | $57.9B | $46.6B | $44.4B |
| Goodwill & Intangibles | $593.8B | $538.7B | $395.4B | $369.9B | $373.2B |
| Long-Term Investments | $127.9B | $144.4B | $161.7B | $72.3B | $81.5B |
| Other Non-Current Assets | $0 | $0 | $22.9B | $0 | $28.1B |
| Total Non-Current Assets | $808.5B | $752.9B | $637.9B | $489.4B | $527.6B |
| Total Assets | $1.31T | $1.13T | $907.5B | $742.6B | $808.1B |
| — Liabilities — | |||||
| Accounts Payable | $22.5B | $13.4B | $38.5B | $38.5B | $56.9B |
| Short-Term Debt | $25.1B | $90.6B | $285.5B | $46.4B | $38.3B |
| Deferred Revenue | $140.0B | $152.0B | $0 | $0 | $0 |
| Other Current Liabilities | $201.6B | $240.0B | $158.5B | $154.0B | $176.3B |
| Total Current Liabilities | $278.4B | $372.7B | $515.5B | $240.6B | $272.7B |
| Long-Term Debt | $244.0B | $244.1B | $133.4B | $259.0B | $179.8B |
| Other Non-Current Liab. | $47.6B | $50.8B | $59.1B | $47.0B | $45.9B |
| Total Non-Current Liabilities | $356.1B | $355.3B | $235.9B | $332.5B | $241.6B |
| Total Liabilities | $634.4B | $728.0B | $751.4B | $573.1B | $514.3B |
| — Equity — | |||||
| Common Stock | $22.4B | $22.4B | $22.4B | $22.4B | $22.5B |
| Retained Earnings | $514.2B | $281.0B | -$22.7B | $46.8B | $159.7B |
| Accumulated OCI | $55.2B | $104.0B | $157.0B | $101.0B | $112.3B |
| Total Stockholders Equity | $607.9B | $406.7B | $156.1B | $169.5B | $293.7B |
| Total Liabilities & Equity | $1.31T | $1.13T | $907.5B | $742.6B | $808.1B |
| — Key Metrics — | |||||
| Total Debt | $284.5B | $346.4B | $418.9B | $305.4B | $218.1B |
| Net Debt | $81.6B | $202.9B | $389.8B | $282.3B | $173.6B |
| Total Investments | $163.5B | $164.6B | $168.8B | $89.2B | $81.5B |